These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

512 related articles for article (PubMed ID: 8589000)

  • 1. Efficacy of recombinant human granulocyte colony-stimulating factor and recombinant human granulocyte-macrophage colony-stimulating factor in neutropenic children with malignancies.
    Lydaki E; Bolonaki E; Stiakaki E; Dimitriou H; Kalmantis T; Kalmanti M
    Pediatr Hematol Oncol; 1995; 12(6):551-8. PubMed ID: 8589000
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recombinant human granulocyte-macrophage colony-stimulating factor in children with chemotherapy-induced neutropenia.
    Saarinen UM; Hovi L; Riikonen P; Pihkala J; Juvonen E
    Med Pediatr Oncol; 1992; 20(6):489-96. PubMed ID: 1435519
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improving treatment of chemotherapy-induced neutropenic fever by administration of colony-stimulating factors.
    Mayordomo JI; Rivera F; Díaz-Puente MT; Lianes P; Colomer R; López-Brea M; López E; Paz-Ares L; Hitt R; García-Ribas I
    J Natl Cancer Inst; 1995 Jun; 87(11):803-8. PubMed ID: 7540696
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of a formulary change from granulocyte colony-stimulating factor to granulocyte-macrophage colony-stimulating factor on outcomes in patients treated with myelosuppressive chemotherapy.
    Wong SF; Chan HO
    Pharmacotherapy; 2005 Mar; 25(3):372-8. PubMed ID: 15843284
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recombinant human granulocyte-macrophage colony-stimulating factor in septic neutropenic pediatric cancer patients: detection of circulating hematopoietic precursor cells correlates with rapid granulocyte recovery.
    Fink FM; Maurer-Dengg K; Fritsch G; Mann G; Zoubek A; Falk M; Gadner H
    Med Pediatr Oncol; 1995 Nov; 25(5):365-71. PubMed ID: 7545780
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Granulocyte-macrophage colony-stimulating factor in patients with neutropenic fever is potent after low-risk but not after high-risk neutropenic chemotherapy regimens: results of a randomized phase III trial.
    Ravaud A; Chevreau C; Cany L; Houyau P; Dohollou N; Roché H; Soubeyran P; Bonichon F; Mihura J; Eghbali H; Tabah I; Bui BN
    J Clin Oncol; 1998 Sep; 16(9):2930-6. PubMed ID: 9738560
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Treatment of chemotherapy-induced neutropenia pegylated recombinant human granulocyte colony-stimulating factor: a multi-center randomized controlled phase II clinical study].
    Shi YK; He XH; Yang S; Wang HQ; Jiang ZF; Zhu YZ; Ke XY; Zhang Y; Liu YP; Zhang WJ; Wang Z; Shi QZ; Xie XD; Zhang HL; Wang JJ; Luo DY; Zheng QS; Sun RY
    Zhonghua Yi Xue Za Zhi; 2006 Dec; 86(48):3414-9. PubMed ID: 17313855
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Granulocyte-macrophage colony-stimulating factor in association with high-dose chemotherapy (VETOPEC) for childhood solid tumors: a report from the Australia and New Zealand Children's Cancer Study Group.
    McCowage GB; White L; Carpenter P; Lockwood L; Toogood I; Tiedemann K; Shaw PJ
    Med Pediatr Oncol; 1997 Aug; 29(2):108-14. PubMed ID: 9180912
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of colony-stimulating factors and granulocyte transfusion in treatment options for neutropenia in children with cancer.
    Liang DC
    Paediatr Drugs; 2003; 5(10):673-84. PubMed ID: 14510625
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative effects of granulocyte-macrophage colony-stimulating factor and granulocyte colony-stimulating factor after high-dose cyclophosphamide cancer therapy.
    Bregni M; Siena S; Di Nicola M; Dodero A; Peccatori F; Ravagnani F; Danesini G; Laffranchi A; Bonadonna G; Gianni AM
    J Clin Oncol; 1996 Feb; 14(2):628-35. PubMed ID: 8636780
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prospective, randomized trial of sequential interleukin-3 and granulocyte- or granulocyte-macrophage colony-stimulating factor after standard-dose chemotherapy in cancer patients.
    Palmeri S; Leonardi V; Danova M; Porta C; Ferrari S; Fincato G; Citarrella P
    Haematologica; 1999 Nov; 84(11):1016-23. PubMed ID: 10553163
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of chemotherapy-induced neutropenia in children with subcutaneously administered recombinant human granulocyte colony-stimulating factor.
    Okamura J; Yokoyama M; Tsukimoto I; Komiyama A; Sakurai M; Imashuku S; Miyazaki S; Ueda K; Hanawa Y; Takaku F
    Pediatr Hematol Oncol; 1992; 9(3):199-207. PubMed ID: 1381941
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hematopoietic growth factors in patients receiving intensive chemotherapy for malignant disorders: studies of granulocyte-colony stimulating factor (G-CSF), granulocyte-macrophage colony stimulating factor (GM-CSF), interleukin-3 (IL-3) and Flt-3 ligand (Flt3L).
    Bruserud O; Foss B; Petersen H
    Eur Cytokine Netw; 2001; 12(2):231-8. PubMed ID: 11399510
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dose-ranging study of recombinant human granulocyte-macrophage colony-stimulating factor in small-cell lung carcinoma.
    Hamm J; Schiller JH; Cuffie C; Oken M; Fisher RI; Shepherd F; Kaiser G
    J Clin Oncol; 1994 Dec; 12(12):2667-76. PubMed ID: 7989942
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential effects of granulocyte-macrophage colony-stimulating factor and granulocyte colony-stimulating factor in children with severe congenital neutropenia.
    Welte K; Zeidler C; Reiter A; Müller W; Odenwald E; Souza L; Riehm H
    Blood; 1990 Mar; 75(5):1056-63. PubMed ID: 1689595
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized trial of sequential administration of G-CSF and GM-CSF vs. G-CSF alone following peripheral blood progenitor cell autograft in solid tumors.
    Recchia F; Accorsi P; Bonfini T; De Filippis S; Grimaldi M; Corrao G; Rosselli M; Amiconi G; Iacone A; Rea S
    J Interferon Cytokine Res; 2000 Feb; 20(2):171-7. PubMed ID: 10714552
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized controlled clinical trial of polyethylene glycol recombinant human granulocyte colony-stimulating factor in the treatment of neutropenia after chemotherapy for breast cancer.
    Huang W; Liu J; Zeng Y; Wu F; Li N; Chen K; Hong Y; Wang L; Zhen H; Lin L
    Cancer Chemother Pharmacol; 2018 Oct; 82(4):607-613. PubMed ID: 30043207
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hematopoietic growth factors for graft failure after bone marrow transplantation: a randomized trial of granulocyte-macrophage colony-stimulating factor (GM-CSF) versus sequential GM-CSF plus granulocyte-CSF.
    Weisdorf DJ; Verfaillie CM; Davies SM; Filipovich AH; Wagner JE; Miller JS; Burroughs J; Ramsay NK; Kersey JH; McGlave PB
    Blood; 1995 Jun; 85(12):3452-6. PubMed ID: 7540062
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sequential administration of interleukin-3 and granulocyte-macrophage colony-stimulating factor following standard-dose combination chemotherapy with etoposide, ifosfamide, and cisplatin.
    Brugger W; Frisch J; Schulz G; Pressler K; Mertelsmann R; Kanz L
    J Clin Oncol; 1992 Sep; 10(9):1452-9. PubMed ID: 1517788
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The efficacy of recombinant human granulocyte colony-stimulating factor and recombinant human granulocyte macrophage colony-stimulating factor in permitting the administration of higher doses of cyclophosphamide in a doxorubicin-cyclophosphamide combination. An NSABP pilot study in patients with metastatic or high-risk primary breast cancer. National Surgical Adjuvant Breast and Bowel Project.
    Mamounas EP; Anderson S; Wickerham DL; Clark R; Stoller R; Hamm JT; Stewart JA; Bear HD; Glass AG; Bornstein R
    Am J Clin Oncol; 1994 Oct; 17(5):374-81; discussion 382. PubMed ID: 7522393
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.